Who makes HPV（0d），HPV（6m），MMR（7m）?

HPV（0d），HPV（6m），MMR（7m） is developed by Zhejiang Provincial Center for Disease Control and Prevention.

What development phase is HPV（0d），HPV（6m），MMR（7m） in?

HPV（0d），HPV（6m），MMR（7m） is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

HPV（0d），HPV（6m），MMR（7m）

Zhejiang Provincial Center for Disease Control and Prevention · FDA-approved active Biologic Quality 0/100

The drug, a combination of HPV (0d), HPV (6m), and MMR (7m) vaccines, is currently marketed by the Zhejiang Provincial Center for Disease Control and Prevention. A key strength is the protection against multiple diseases, leveraging a single vaccination schedule. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition.

At a glance

Generic name	HPV（0d），HPV（6m），MMR（7m）
Sponsor	Zhejiang Provincial Center for Disease Control and Prevention
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HPV（0d），HPV（6m），MMR（7m） CI brief — competitive landscape report
HPV（0d），HPV（6m），MMR（7m） updates RSS · CI watch RSS
Zhejiang Provincial Center for Disease Control and Prevention portfolio CI